Anika Therapeutics Inc (NAS:ANIK)
$ 17.35 -0.2 (-1.14%) Market Cap: 254.10 Mil Enterprise Value: 219.27 Mil PE Ratio: 0 PB Ratio: 1.42 GF Score: 70/100

Anika Therapeutics Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript

Sep 17, 2020 / 12:45PM GMT
Release Date Price: $36.69 (-1.05%)
Peter Harrison

Good morning. This is Peter Harrison. I run Morgan Stanley's medtech investment banking efforts.

Before we get started, a quick disclaimer. Please note that this webcast is for Morgan Stanley's clients and appropriate Morgan Stanley employees only. This webcast is not for members of the press. If you are a member of the press, please disconnect and reach out separately. For important disclosures, please see the Morgan Stanley Research disclosure website at www.morganstanley.com\researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative.

Thanks for being with us today. I want to welcome Anika Therapeutics at the conference. With us today is Cheryl Blanchard, CEO; and Mike Levitz, CFO.

To get us started, why don't we -- Cheryl, why don't you talk a little bit about the story for those less familiar to Anika, and then we'll move on for some questions. Also, there is a question portal. If you have any questions, please submit them, and I'll be monitoring that and ask them as appropriate. Cheryl?

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot